Corporate profile

History

Miraculins began operations in 2002 as a research and development company focused on biomarker discovery using its proprietary B.E.S.T Platform™ for the screening and identification of target proteins and peptides related to diseases.

Miraculins was initially founded as a company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products.

Miraculins' original vision was to save lives through the early detection and diagnosis of cancer and to contribute substantially to the overall diagnosis and treatment of cancer by the Company’s leadership in the discovery and development of biomarker diagnostics to improve the information available to physicians and consequently enhance the quality of treatment for cancer patients.

New Business Model

In June of 2008, Miraculins announced a shift in its business model that moves the Company’s focus further down the diagnostic assay development and commercialization pathway.

The Company’s business plan now focuses on in-licensing/acquiring and developing both cancer and non-cancer diagnostic opportunities that have completed early stage research and address unmet clinical needs. The Company has moved away from basic proteomic research and discovery to focus on diagnostic development and commercialization.

Director of Research and Development

Concurrent to the decision to shift the company’s focus and acquire new technologies Miraculins appointed Dr. Steve Frost to lead the Company’s research and development program as the Director of Research & Development. 

Previous to his appointment, Dr. Frost worked in Abbott Laboratories Diagnostics Division for over 15 years.  During his tenure at Abbott, Dr. Frost was responsible for the evaluation of oncology assays available for license or acquisition from university and industry sources.  Additionally, Dr. Frost was the project manager for numerous high-profile projects in the area of cancer, women’s health and infectious disease diagnostics, and was responsible for the design and execution of feasibility and validation studies while supporting the manufacturing and quality control functions for the project.  Dr. Frost was also responsible for building and managing various dynamic teams for the achievement of development goals related to the project.  Of further note, Dr. Frost developed an algorithm during his time at Abbott which demonstrates the ability to improve on the detection accuracy of a panel of lung cancer biomarkers.

Under the direction of Dr. Frost, Miraculins is constantly reviewing hundreds of available technologies from research institutions across the globe.